Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Terminated Not applicable Interventional

Impact of Intraoperative Cell Salvage

NCT06240117
Conditions
Peripartum Anemia
Interventions
Intraoperative cellular salvage
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Duarte, California
Conditions
CNS Cancer, CNS BRAIN
Interventions
temozolomide followed by high dose busulfan and thiotepa
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

CAREgiver Study for Patients Undergoing HSCT

NCT03210727
Conditions
Neoplasms
Interventions
Ready to CARE program
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions
pyrazoloacridine, filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis, pharmacological study
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes, in vitro-treated peripheral blood stem cell transplantation, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, filgrastim, aldesleukin
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Sarcoma
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, ifosfamide, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
10 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2014
U.S. locations
1
States / cities
Duarte, California
Conditions
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
Interventions
paclitaxel, ifosfamide, cisplatin, pegylated G-CSF, G-CSF, carboplatin, etoposide phosphate, stem cell reinfusion
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
14 Years and older · Male only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more
Conditions
Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
Interventions
Rapidly generated virus specific T (R-MVST) cells
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Systemic Lupus Erythematosus
Interventions
anti-thymocyte globulin, cyclophosphamide, filgrastim, CD34+ Peripheral Blood Stem Cell Reinfusion
Drug · Procedure
Lead sponsor
Northwestern Memorial Hospital
Other
Eligibility
0 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Conditions
Lymphoma
Interventions
rituximab, bendamustine, melphalan, Autologous Stem Cell Transplantation (ASCT)
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
etoposide phosphate, melphalan, topotecan, Autologous Stem Cell Rescue
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 69 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Acute Myeloid Leukemia (AML)
Interventions
G-CSF, Leukapheresis, Busulfan, Stem cell reinfusion
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
56 Years to 74 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Medulloblastoma, Central Nervous System Embryonal Tumors
Interventions
Induction, Single Cycle Intensive Chemotherapy, Tandem 3 Cycle Intensive Chemotherapy
Drug
Lead sponsor
Parth Patel
Other
Eligibility
Up to 10 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
filgrastim, carboplatin, etoposide, isotretinoin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more
Conditions
Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
Interventions
Viral specific VST Infusion
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Weeks and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
3
States / cities
Akron, Ohio • Cincinnati, Ohio
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, cisplatin, cyclophosphamide, etoposide, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 10 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
29
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more
Conditions
Multiple Myeloma
Interventions
Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Lymphoma
Interventions
filgrastim, rituximab, Carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
17 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota